Healthcare CMO

Global Healthcare CMO Market to Reach US$291.1 Billion by 2030

The global market for Healthcare CMO estimated at US$158.7 Billion in the year 2024, is expected to reach US$291.1 Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2024-2030. Pharmaceutical CMO, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$185.0 Billion by the end of the analysis period. Growth in the Medical Device CMO segment is estimated at 13.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$43.2 Billion While China is Forecast to Grow at 14.2% CAGR

The Healthcare CMO market in the U.S. is estimated at US$43.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$59.2 Billion by the year 2030 trailing a CAGR of 14.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.8% and 9.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Healthcare CMO Market - Key Trends & Drivers Summarized

Why Are Contract Manufacturing Organizations Becoming Integral to Healthcare Supply Chains?

Healthcare Contract Manufacturing Organizations (CMOs) provide outsourced manufacturing services for pharmaceutical products, medical devices, and biologics. These organizations handle complex tasks ranging from formulation and production to packaging and distribution. As healthcare companies face pressure to reduce costs, accelerate time-to-market, and maintain regulatory compliance, CMOs are playing an increasingly central role in production strategies.

CMOs offer access to specialized facilities and technical expertise without requiring capital-intensive infrastructure investments by the healthcare brand owner. This is particularly valuable for small and mid-sized firms developing niche therapies or medical technologies. Larger companies are also leveraging CMOs to increase manufacturing flexibility, manage demand surges, and enter new markets with local production capabilities.

How Are CMOs Expanding Capabilities Across Pharmaceuticals and Medtech?

Pharmaceutical CMOs are enhancing capabilities in high-potency drug production, sterile injectables, and continuous manufacturing. Biologics manufacturing, including monoclonal antibodies and cell therapies, is seeing significant investment in upstream and downstream processing capacity. CMOs are expanding fill-finish services, cold chain logistics, and advanced packaging for sensitive formulations.

In the medical device sector, CMOs are incorporating precision tooling, additive manufacturing, and automation to meet the stringent requirements of surgical, diagnostic, and wearable devices. Electronic component integration, sterilization services, and quality documentation are critical capabilities being scaled up for compliance with international regulatory frameworks. Many CMOs now offer end-to-end services from design assistance to regulatory submissions and post-market support, consolidating their role in product lifecycle management.

Where Is CMO Demand Rising and Which Therapeutic Areas Lead Outsourcing Activity?

Demand for CMO services is rising in North America, Europe, and Asia-Pacific, with regional differences in service specialization and therapeutic focus. Oncology, autoimmune diseases, and rare conditions are key areas driving pharmaceutical outsourcing due to complex manufacturing needs and targeted treatment models. For medical devices, demand is strongest in diagnostics, minimally invasive surgery, and connected health solutions.

Biotech firms with limited in-house infrastructure are increasingly relying on CMOs for both clinical trial materials and commercial-scale production. Established pharma companies are outsourcing mature product lines to CMOs in lower-cost regions to optimize internal resources. In diagnostics, CMOs are supporting rapid scaling of assay kits, reagents, and instrument components in response to global health demands. These patterns are reinforcing CMO relevance across clinical and commercial supply chains.

What Is Driving Growth in the Healthcare CMO Market?

Growth in the healthcare CMO market is driven by several factors related to manufacturing specialization, therapeutic complexity, and supply chain optimization. Rising development of biologics, sterile injectables, and personalized medicines is encouraging use of contract manufacturers with specialized infrastructure. Advances in automation, compliance systems, and high-throughput production are improving operational efficiency and regulatory alignment. Growth is also supported by increased outsourcing of low-margin legacy products, entry of virtual biotech companies, and expansion of global pharmaceutical pipelines. As healthcare firms seek leaner operations and technical scale-up, CMOs are becoming critical production partners across drugs and devices.

SCOPE OF STUDY:

The report analyzes the Healthcare CMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Pharmaceutical CMO, Medical Device CMO)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Almac Group
• AMRI (Albany Molecular Research Inc.)
• Boehringer Ingelheim BioXcellence
• Catalent, Inc.
• CordenPharma International GmbH
• Emergent BioSolutions Inc.
• Famar Health Care Services
• Fareva Group
• Grifols International S.A.
• Jubilant Pharmova Ltd.
• Lonza Group AG
• Patheon (by Thermo Fisher Scientific)
• PCI Pharma Services
• Pfizer CentreOne
• Piramal Pharma Solutions
• Recipharm AB
• Samsung Biologics
• Siegfried Holding AG
• Thermo Fisher Scientific Inc.
• Wuxi AppTec

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more